

Deallus Candidate Case Assignment: JAK Inhibitors

Instructions:

- Your task is to prepare a 15 minute power point presentation, maximum 10 slides (excluding appendices)
- The preparation time for this assignment should not exceed 8-12 hours
- Suggested resources: <u>www.clinicaltrials.gov</u>, company websites, Thomson Reuters etc.

Background:

The Janus kinase (JAK) family of intracellular transducers of cytokine-mediated signalling was identified in the early 1990s. Since then, JAKs have been associated with a number of diseases, including various inflammatory disorders and various types of malignancy. A number of JAK inhibitors have been developed and are currently undergoing clinical evaluation. Importantly, many of the inhibitors are not monospecific and there is cross reactivity to other JAK family members.

Assignment:

Prepare a 15 minute power point presentation, including;

- A succinct and insightful introduction to JAK translational/clinical science, summarizing the relevance of the JAKs in human disease and the therapeutic potential of inhibition (one slide only)
- Create an overview of all JAK inhibitors (JAK-1, 2 & 3) under Phase II and Phase III clinical investigation, as well as the marketed products, focusing on their clinical development strategy (which indication(s) is/are the company pursuing and what are the company's goals for their asset?)
- In your opinion, which of these candidates has the biggest opportunity for long-term commercial (total revenue and/or market share or other) success?

Please be prepared to defend your reasoning and include quantitative figures as necessary. We are also interested to assess your ability to present complex ideas in a visual and thought-stimulating way, thus please be aware that the presentation in itself also delivers some of these aspects. We are interested to hear your recommendations and, most importantly, to learn how you structure your train of thought to reach your conclusions.

